Sulfaphenazole and α-Naphthoflavone attenuate the metabolism of the synthetic cannabinoids JWH-018 and AM2201 Found in K2/Spice

Drug Metabolism Letters

Volumn 7, Issue 1, 2013, Pages 34-38

  Chimalakonda, Krishna C ^a   James, Laura P ^a   Radominska Pandya, Anna ^a   Moran, Jeffery H ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b ARKANSAS DEPARTMENT OF HEALTH   (United States)

Author keywords

AM2201; Cytochrome P450; JWH 018; K2 Spice; Synthetic cannabinoids

Indexed keywords

3 (1 NAPHTHOYL) 1 PENTYLINDOLE; ALPHA NAPHTHOFLAVONE; AM2201; CANNABINOID 1 RECEPTOR AGONIST; KETOCONAZOLE; OMEPRAZOLE; QUINIDINE; SULFAPHENAZOLE; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; DRUG ABUSE; DRUG EFFECT; DRUG OXIDATION; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LIVER CELL; MALE; METABOLIC INHIBITION; MICROSOME; NORMAL HUMAN; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZOFLAVONES; CANNABINOIDS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; MALE; MICROSOMES, LIVER; NAPHTHALENES; OXIDATION-REDUCTION; STREET DRUGS; SULFAPHENAZOLE;

EID: 84891847249     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231280701131211151523     Document Type: Article

References (10)

1. Seely, K.A.; Lapoint, J.; Moran, J.H.; Fattore, L. Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2012, 39(2), 234-43.
2. Brents, L.K.; Reichard, E.E.; Zimmerman, S.M.; Moran, J.H.; Fantegrossi, W.E.; Prather, P.L. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One, 2011, 6(7), e21917
3. Chimalakonda, K.C.; Seely, K.A.; Bratton, S.M.; Brents, L.K.; Moran, C.L.; Endres, G.W.; James, L.P.; Hollenberg, P.F.; Prather, P.L.; Radominska-Pandya, A.; Moran, J.H. Cytochrome P450-mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in "K2/Spice": Identification of Novel Cannabinoid Receptor Ligands. Drug Metab. Dispos., 2012, 40(11), 2174-84.
4. Chimalakonda, K.C.; Bratton, S.M.; Le, V.H.; Yiew, K.H.; Dineva, A.; Moran, C.L.; James, L.P.; Moran, J.H.; Radominska-Pandya, A. Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases. Drug Metab. Dispos., 2011, 39(10), 1967-76.
5. Rodrigues, A.D. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem. Pharmacol., 1999, 57(5), 465-80.
6. Newton, D.J.; Wang, R.W.; Lu, A.Y. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos., 1995, 23(1), 154-8
7. Rodrigues, A.D., In Drug-Drug Interactions: Drugs and the Pharmaceutical Sciences, ed., A.D. Rodrigues. Marcel Dekker, Inc. New York, 2002 2002, 116.
8. Paine, M.F.; Hart, H.L.; Ludington, S.S.; Haining, R.L.; Rettie, A.E.; Zeldin, D.C. The human intestinal cytochrome P450 "pie". Drug Metab. Dispos., 2006, 34(5), 880-6.
9. Seng, K.C.; Gan, G.; Sangkar, V.J.; Phipps, M.E. Frequency of Cytochrome P450 2C9 (CYP2C9) Alleles in Three Ethnic Groups in Malaysia. Asia Pacific J. Mol. Biol. Biotechnol., 2003, 11(2), 9.
10. Gunes, A.; Dahl, M.L. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics, 2008, 9(5), 625-37.